8095
Fiscal year ends November Quarters are offset from the calendar — Q1 is Dec–Feb

Astena Holdings Co., Ltd. is a diversified group operating in fine chemicals, health and beauty care, pharmaceuticals, and industrial chemicals. The fine chemicals segment focuses on contract research, development, and manufacturing for pharmaceuticals, including peptide synthesis and process development, through subsidiaries such as Spela Pharma and Spela Nexus. The health and beauty care and food segment involves the manufacturing and sale of cosmetics, functional food ingredients, and supplements, with key brands including Torriden and Pureal, and subsidiaries like Iwaki and Maruman H&B. The pharmaceuticals segment covers the production and distribution of medical and general pharmaceuticals via Iwaki Pharmaceutical. The chemicals segment provides electronic industrial chemicals, surface treatment agents, and printed circuit boards through Meltex and Tokyo Kakoki. The group also engages in social impact initiatives and regional development projects. Founded in 1914, the company serves markets in Japan, North America, and Asia.

Summarised from the annual report, fiscal year ended Nov 2025

Industry Specialty Chemicals Homepage astena-hd.com
Sector Basic Materials IR page astena-hd.com/ir
Tags
fine chemicals, pharmaceutical cmc, peptide synthesis, cosmetics manufacturing, functional food ingredients, surface treatment chemicals, printed circuit boards, health supplements, contract manufacturing, Spela Pharma, Spela Nexus, JITSUBO, Iwaki Pharmaceutical Sakura Plant, Iwaki, Aplus, Maruman H&B, Ains Lab, Ikeda Sangyo, Ikeda Bussan, Innovation, Ikeda Corporation of America, Boen Chemical, Iwaki Pharmaceutical, Meltex, Tokai Meltex, Tokyo Kakoki, Meltex Hong Kong, Taiwan Meltex, Meltex Asia Thailand, Meiluda Technology (Tianjin), Meltex Korea, Hongsu Electronic Equipment (Shanghai), Tokyo Kakoki Co. Ltd. (Cayman), Astena Minerva, NAIA, Astena Heartful, Okunoto SDGs Investment Fund, Torriden, Pureal, NeoGuard+ NS30
Press page astena-hd.com/media/news

Metrics

Valuation  
Market cap ¥ 21.497B
Market cap (USD) $ 134.359M
P/E 8.24
PEG 0.15
P/BV 0.74
P/S 0.31
P/OCF 6.34
P/FCF 98.61
Dividend yield 3.4%
Turnover / mcap —
Returns  
ROE 8.3%
ROI 4.4%
ROIC 4.6%
Profit margin 3.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 55.7%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue 62.744B 57.993B 51.984B 49.636B 72.322B 65.341B 61.648B 60.084B 57.388B 55.122B 55.423B 54.145B 52.465B 51.954B
Net profit 2.187B -2.525B 1.163B 579.604M 1.737B 1.984B 1.533B 1.415B 1.242B 8.36M -143.787M 496.275M 744.74M 728.415M
Free cash flow 218M 1.65B -2.521B -3.513B -2.145B 2.39B 108.722M 839.366M 1.099B 369.429M 1.893B — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price 477 483.02 497.19 417.01 486.15 525.55 473.69 528.55 489.22 207.31 222.17 227.73 214.03 166.17
Price performance 12m -0.01 -0.03 0.19 -0.14 -0.07 0.11 -0.1 0.08 1.36 -0.07 -0.02 0.06 0.29 —

Filed figures

Figure Nov 2016 Nov 2017 Nov 2018 Nov 2019 Nov 2020 Nov 2021 Nov 2022 Nov 2023 Nov 2024 Nov 2025
Balance sheet detail
Trade receivables (JPY) 15.6B 16B 16.7B 18.1B 15B 16.7B 17.7B 17.3B 19.5B 22.9B
↳ YoY growth +5.3% +2.7% +4.4% +8.5% -17.1% +11.2% +6.0% -2.3% +12.8% +17.5%
↳ 5y CAGR +0.3% +1.4% +2.1% +0.7% +1.5% +8.8%
Other receivables (JPY) 276M 388M 391M 337M 569M 692M 697M 358M 595M —
Borrowings, current (JPY) 2.06B 2.6B 3.3B 3.8B 5.97B 9.05B 10B 12.3B 11.4B 16.2B
Borrowings, non-current (JPY) 980M 549M 452M 805M 5.97B 5.81B 4.78B 4.49B 3.45B 6.25B
Lease liabilities (JPY) 288M 228M 237M 217M 206M 187M 137M 146M 86.2M 141M
Cash and deposits (JPY) 4.18B 4.93B 4.75B 4.92B 7.57B 10.9B 6.93B 6.88B 6.1B 10.2B
Intangible assets (JPY) 79.3M 78.3M 1.13B 1.46B 7.47B 8.41B 8.29B 7.46B 6.89B 7.64B
Net debt (borrowings + leases - cash) (JPY) -848M -1.56B -760M -97.2M 4.58B 4.13B 8.02B 10B 8.82B 12.4B
Cash flow detail
Operating cash flow (JPY) 954M 1.52B 1.66B 1.6B 4.14B 1.35B -742M 1.64B 4.85B 3.39B
Purchases of property, plant and equipment (JPY) -584M -403M -681M -1.09B -1.31B -2.94B -2.77B -3.82B -2.84B -2.89B
Purchases of intangible assets (JPY) -24.8M -21.2M -135M -401M -445M -559M -259M -344M -357M -282M
Change in receivables (cash effect) (JPY) -787M -561M -730M -979M 3.85B -1.06B -95.3M 338M -2.13B 487M
Change in inventories (cash effect) (JPY) 582M -469M -649M -1.24B -381M -575M -961M -1.29B 383M -826M
Change in payables (cash effect) (JPY) -551M 1.1B 307M 1.05B -1.99B -173M -14.6M -298M 1.52B -140M
Dividends paid (cash effect) (JPY) -200M -199M -317M -385M -471M -651M -729M -719M -727M -735M
Share buybacks (cash effect) (JPY) -107M -447M -1.25M -102,000 -88,000 -4.41M -310M -58,000 -6.66M 0.00
Interest paid (cash effect) (JPY) -35.1M -25.3M -22.6M -21.3M -41.1M -61.4M -53.6M -60.1M -74M -157M
Income taxes paid (cash effect) (JPY) -481M -608M -487M -714M -1.19B -1.02B -1.26B -1.44B -894M -1.07B
Share-based compensation (JPY) — 105M 119M 55.9M 48.4M 43.8M 50.5M 86.4M 48.1M 68M
Operating cash flow before change in receivables (JPY) 1.74B 2.08B 2.39B 2.58B 297M 2.41B -647M 1.31B 6.98B 2.91B
Free cash flow (OCF - PPE - intangibles) (JPY) 345M 1.1B 839M 109M 2.39B -2.14B -3.77B -2.52B 1.65B 218M
Income detail
Research and development expense (JPY) 833M 731M 810M 735M 768M 964M 825M 895M 1.05B 971M
↳ 5y CAGR -4.9% +3.0% +2.4% +2.0% +7.5% +4.8%
Total comprehensive income (JPY) -869M 1.66B 1.51B 1.49B 1.59B 1.75B 783M 2.09B -2.6B 2.61B
Comprehensive income to owners (JPY) -873M 1.64B 1.51B 1.48B 1.59B 1.75B 788M 2.1B -2.59B 2.62B
Provision for credit losses (JPY) 16M 18.6M 32.4M 11.4M 10.6M 12M 1.36M -2.27M 791,000 0.00
Credit cost ratio (credit losses / average receivables) (%) 0.1% 0.1% 0.2% 0.1% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0%
Reported Feb 23, 2018 Feb 23, 2018 Feb 22, 2019 Feb 26, 2020 Feb 24, 2021 Feb 25, 2022 Feb 22, 2023 Feb 28, 2024 Feb 27, 2025 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

NAIA、「Biople FES OSAKA 2026」に初出店! Bull 1 Bear 0 Product/operations

2026年9月16日(水)~20日(日)、阪急うめだ本店9階 祝祭広場で開催された「Biople FES OSAKA 2026」に、NAIAとして初めて出展しました。今回の出展は、ナチュラル&オーガニックへの関心が高いBiopleのお客様に、能登の自然素材と科学的知見を融合したNAIAの商品を実際に手に取っていただき、ブランド認知の拡大と新たなお客様との接点づくりを目的に参加したものです。

会場は連日多くのお客様で賑わい、NAIAブースにも幅広い年代の方にお立ち寄りいただきました。特にラフマ茶の試飲には、約1,000名の方にご体験いただき、味わいや素材について直接ご紹介することができました。試飲をきっかけに商品について質問をいただいたり、能登の素材やNAIAのものづくりに興味を持っていただいたりするなど、多くのお客様と直接コミュニケーションを取る貴重な機会となりました。

NAIAブースでは、能登の素材を生かしたスキンケアやボディケア商品をはじめ、ラフマ茶や能登ヒバを使用した商品などを展開しました。なかでもラフマ茶と能登ヒバ バスソルトは想定を上回る反響をいただき、ほぼ完売となりました。また、FES限定のスキンケアトライアルセットやハンドケアセットもご用意し、商品を試していただくだけでなく、素材の背景や能登でのものづくりについて直接お伝えすることで、NAIAならではのブランドストーリーに触れていただく機会となりました。

今回初めてBiople FESに出展し、実際にお客様とお話しすることで、どの商品やストーリーに興味を持っていただけるのかを直接知ることができました。特にラフマ茶や能登ヒバ バスソルトへの反応が想定以上に高く、Biopleのお客様とNAIAとの高い親和性を実感しました。今回得られた声や手応えを、今後の商品開発や販売活動につなげていきたいと思います。

Prompts

Astena Holdings Co., Ltd. (ticker 8095), listed in Japan.

ETFs Holding Astena Holdings Co., Ltd.

ETF Weight in ETF Shares Market value As of
DISV 0.01% 158,600 $ 550.488K Nov 12, 2026
DFIS 0.00% 72,900 $ 253.03K Nov 12, 2026
DFIC 0.00% 52,200 $ 181.182K Nov 12, 2026
DFAX 0.00% 30,400 $ 105.516K Nov 12, 2026
DFSI 0.00% 2,600 $ 9,024.39 Nov 12, 2026
DXIV 0.00% 300 $ 1,041.28 Nov 12, 2026
DFAI 0.00% 15,400 $ 53.452K Nov 12, 2026
AVDE 0.00% 4,500 $ 15.358K Nov 16, 2026
AVDV 0.00% 28,800 $ 98.289K Nov 16, 2026
AVSD 0.00% 3,000 $ 10.238K Nov 16, 2026
AVDS 0.00% 2,400 $ 8,190.74 Nov 16, 2026